Pharma BD Deal Intelligence
Vor Biopharma amended its June 2025 exclusive license agreement with RemeGen Co., Ltd. to add RC298, RemeGen's proprietary dual-target BAFF/APRIL fusion protein, and certain related compounds as additional licensed products alongside telitacicept. Vor holds development and commercialization rights in all territories outside Greater China. Consideration for the expansion comprises $10 million in cash plus a pre-funded warrant for 2.3 million shares exercisable at $0.0001, with up to $330 million in milestones tied to initial products, up to $300 million tied to additional products, and up to $3.775 billion in sales milestones, plus tiered royalties in the high single-digit to mid-teen percentage range.
← Browse all deals · How we score deals
More: 2026 deals